Abstract:BACKGROUND:Randomized controlled trials are considered the gold standard for evaluating experimental treatments but often require large sample sizes. Single-arm trials require smaller sample sizes but are subject to bias when using historical control data for comparative inferences. This article presents a Bayesian adaptive synthetic-control design that exploits historical control data to create a hybrid of a single-arm trial and a randomized controlled trial.METHODS:The Bayesian adaptive synthetic control design has two stages. In stage 1, a prespecified number of patients are enrolled in a single arm given the experimental treatment. Based on the stage 1 data, applying propensity score matching and Bayesian posterior prediction methods, the usefulness of the historical control data for identifying a pseudo sample of matched synthetic-control patients for making comparative inferences is evaluated. If a sufficient number of synthetic controls can be identified, the single-arm trial is continued. If not, the trial is switched to a randomized controlled trial. The performance of The Bayesian adaptive synthetic control design is evaluated by computer simulation.RESULTS:The Bayesian adaptive synthetic control design achieves power and unbiasedness similar to a randomized controlled trial but on average requires a much smaller sample size, provided that the historical control data patients are sufficiently comparable to the trial patients so that a good number of matched controls can be identified in the historical control data. Compared to a single-arm trial, The Bayesian adaptive synthetic control design yields much higher power and much smaller bias.CONCLUSION:The Bayesian adaptive synthetic-control design provides a useful tool for exploiting historical control data to improve the efficiency of single-arm phase II clinical trials, while addressing the problem of bias when comparing trial results to historical control data. The proposed design achieves power similar to a randomized controlled trial but may require a substantially smaller sample size.

Subgroup-Based Adaptive (SUBA) Designs for Multi-arm Biomarker Trials

Leveraging machine learning: Covariate-adjusted Bayesian adaptive randomization and subgroup discovery in multi-arm survival trials

BLAST: Bayesian Latent Subgroup Design for Basket Trials Accounting for Patient Heterogeneity

A Bayesian Group Sequential Design for Randomized Biosimilar Clinical Trials with Adaptive Information Borrowing from Historical Data

Bayesian Group Sequential Enrichment Designs Based on Adaptive Regression of Response and Survival Time on Baseline Biomarkers.

Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imperfectly Measured Biomarkers

A Utility-Based Design for Randomized Comparative Trials with Ordinal Outcomes and Prognostic Subgroups

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

Optimal Biomarker-Guided Design for Targeted Therapy with Imperfectly Measured Biomarkers

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Hierarchical Bayesian Clustering Design of Multiple Biomarker Subgroups (HCOMBS)

A Nonparametric Bayesian Basket Trial Design

A Bayesian Response-Adaptive Covariate-Balanced Randomization Design with Application to A Leukemia Clinical Trial

Optimal predictive probability designs for randomized biomarker-guided oncology trials

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

Biomarker-Driven Oncology Trial Design and Subgroup Characterization: Challenges and Potential Solutions

Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses

Optimal Marker-Strategy Clinical Trial Design to Detect Predictive Markers for Targeted Therapy

A signature enrichment design with Bayesian adaptive randomization

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

Multiplicity for a Group Sequential Trial with Biomarker Subpopulations